ReviewMediterranean journal of rheumatology2020
Basic Mechanisms of JAK Inhibition.
Review in Mediterranean journal of rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial.Journal of Crohn's & colitis · 2024Trial
- The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.Pediatric rheumatology online journal · 2026Article
- Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- 3D-QSAR and free energy landscape analysis for predicting novel JAK3 inhibitors in rheumatoid arthritis therapy.Scientific reports · 2026Article
- Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health science reports · 2026Review
- Advances in Crohn's Disease: A Comprehensive Review of Pathophysiology, Diagnosis, and Emerging Therapeutics.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.Pharmaceutics · 2026Review
- JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.Cancers · 2026Review
- MDI1228, a topical pan-JAK inhibitor, disrupts dermal fibroblast-T cell chemokine crosstalk to resolve allergic contact and atopic dermatitis.Frontiers in immunology · 2026Article
- Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.Frontiers in immunology · 2026Review
- Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- The use of Janus kinase inhibitors to treat noninfectious uveitis.Eye (London, England) · 2026Article
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- Article
- Emerging role of Janus kinase inhibitors in ulcerative colitis management.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Advances in the treatment of systemic lupus erythematosus.Nature reviews. Drug discovery · 2025Review
- Sweet syndrome successfully treated with upadacitinib.JAAD case reports · 2025Article
- The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient.JAAD case reports · 2025Article
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.Dermatology and therapy · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.